» Articles » PMID: 37505857

Analysis of Functional Promoter of Camel FGF21 Gene and Identification of Small Compounds Targeting FGF21 Protein

Overview
Journal Vet Sci
Publisher MDPI
Date 2023 Jul 28
PMID 37505857
Authors
Affiliations
Soon will be listed here.
Abstract

The fibroblast growth factor 21 (FGF21) gene plays an important role in the mechanism of glucose and lipid metabolism and is a promising therapeutic target for metabolic disease. Camels display a unique regulation characteristic of glucose and lipid metabolism, endowing them with the ability to adapt to survive drought and chronic hunger. However, the knowledge about the camel FGF21 gene regulation and its differences between humans and mice is still limited. In this study, camel FGF21 gene promoter was obtained for ~2000 bp upstream of the transcriptional start site (TSS). Bioinformatics analysis showed that the proximal promoter region sequences near the TSS between humans and camels have high similarity. Two potential core active regions are located in the -445-612 bp region. In addition, camel FGF21 promoter contains three CpG islands (CGIs), located in the -435~-1168 bp regions, significantly more and longer than in humans and mice. The transcription factor binding prediction showed that most transcription factors, including major functional transcription factors, are the same in different species although the binding site positions in the promoter are different. These results indicated that the signaling pathways involved in FGF21 gene transcription regulation are conservative in mammals. Truncated fragments recombinant vectors and luciferase reporter assay determined that camel FGF21 core promoter is located within the 800 bp region upstream of the TSS and an enhancer may exist between the -1000 and -2000 bp region. Combining molecular docking and in silico ADMET druggability prediction, two compounds were screened as the most promising candidate drugs specifically targeting FGF21. This study expanded the functions of these small molecules and provided a foundation for drug development targeting FGF21.

Citing Articles

Establishment of a Direct Competitive ELISA for Camel FGF21 Detection.

Yang Y, Yuan H, Jiao Y, Zhao S, Fu Y, Bai X Vet Sci. 2025; 12(2).

PMID: 40005931 PMC: 11861717. DOI: 10.3390/vetsci12020170.

References
1.
Haberle V, Stark A . Eukaryotic core promoters and the functional basis of transcription initiation. Nat Rev Mol Cell Biol. 2018; 19(10):621-637. PMC: 6205604. DOI: 10.1038/s41580-018-0028-8. View

2.
Weng Y, Ishino T, Sievers A, Talukdar S, Chabot J, Tam A . Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing. Sci Rep. 2018; 8(1):4241. PMC: 5844872. DOI: 10.1038/s41598-018-22456-w. View

3.
Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M . An atlas of active enhancers across human cell types and tissues. Nature. 2014; 507(7493):455-461. PMC: 5215096. DOI: 10.1038/nature12787. View

4.
Hughes A, Szczurek A, Kelley J, Lastuvkova A, Turberfield A, Dimitrova E . A CpG island-encoded mechanism protects genes from premature transcription termination. Nat Commun. 2023; 14(1):726. PMC: 9911701. DOI: 10.1038/s41467-023-36236-2. View

5.
Stanzione F, Giangreco I, Cole J . Use of molecular docking computational tools in drug discovery. Prog Med Chem. 2021; 60:273-343. DOI: 10.1016/bs.pmch.2021.01.004. View